Vitamin D3 vs D2: Bioavailability, Cofactors, and Evidence-Based Dosing

Vitamin D exists in two supplemental forms: D3 (cholecalciferol) and D2 (ergocalciferol). While both contribute to serum 25-hydroxyvitamin D levels — the standard clinical biomarker — their potency is not equivalent. A meta-analysis of randomized controlled trials found that D3 is approximately 87% more effective than D2 at raising and maintaining serum 25(OH)D concentrations over time.

The difference stems from pharmacokinetics. D3 has a higher binding affinity for vitamin D-binding protein (DBP), giving it a longer circulating half-life. D2 is metabolized more rapidly and produces metabolites that compete with 25(OH)D3 for receptor binding — meaning D2 supplementation can actually reduce the concentration of the most biologically active vitamin D metabolite.

D2 (ergocalciferol) is synthesized by fungi and yeast when exposed to UV radiation. It remains the historically prescribed pharmaceutical form and is the only option for strict vegans who avoid lanolin-sourced D3. However, for the goal of efficiently raising serum 25(OH)D, D3 is the form supported by the strongest evidence. FormulaForge uses Vitamin D3 (cholecalciferol) exclusively, scoring 84/100 on our proprietary bioavailability scale versus 47/100 for D2.

Standard vitamin D3 requires two hydroxylation steps before becoming biologically active: first in the liver (producing 25-hydroxyvitamin D3, or calcidiol), then in the kidneys (producing 1,25-dihydroxyvitamin D3, or calcitriol). For most healthy adults, this conversion is efficient. But for individuals with fat malabsorption conditions, liver dysfunction, obesity, or post-bariatric surgery status, the first hepatic hydroxylation can be a rate-limiting bottleneck.

Calcidiol — also marketed as Hy-D (calcifediol) — bypasses the liver conversion step entirely. It is already 25-hydroxylated, meaning it enters circulation in the same form that clinicians measure on a standard blood test. Research shows calcidiol raises serum 25(OH)D levels approximately 2-3x more effectively than an equivalent dose of standard D3, with a more linear dose-response curve.

For individuals who have tested persistently low despite standard D3 supplementation, calcidiol represents a mechanistically distinct approach. It is particularly relevant for those with compromised fat absorption, as calcidiol is more water-soluble than D3 and less dependent on micellar absorption in the gut.

FormulaForge recognizes calcidiol as an emerging premium form. For most healthy adults, D3 (cholecalciferol) remains the efficient, well-researched first choice. Calcidiol is the specialist upgrade for documented absorption challenges.

Vitamin D3 does not operate in isolation. Two cofactors are required for D3 to fulfill its role in calcium metabolism and bone health: vitamin K2 and magnesium. Supplementing D3 without these cofactors is like filling a bathtub without a drain and a faucet handle — the system is incomplete.

Vitamin K2 (specifically the MK-7 subtype) activates osteocalcin and matrix Gla protein (MGP) — two proteins that direct calcium into bones and teeth while keeping it out of soft tissues like arteries and kidneys. Without adequate K2, increased calcium absorption from D3 supplementation may deposit in arterial walls rather than bone matrix. A growing body of research supports the synergy between D3 and K2 for maintaining healthy calcium distribution.

Magnesium is required for the enzymatic conversion of vitamin D3 into its active forms. The cytochrome P450 enzymes responsible for both the hepatic (25-hydroxylation) and renal (1-alpha-hydroxylation) steps are magnesium-dependent. Research estimates that up to 50% of Americans consume insufficient magnesium, meaning their vitamin D supplementation may be limited by cofactor availability rather than D3 intake itself.

FormulaForge formulations pair D3 with K2 (MK-7) and bioavailable magnesium (as Bisglycinate) by default in our recommended stacks. This cofactor-complete approach reflects the current evidence on how these nutrients interact in calcium and bone metabolism.

Vitamin D dosing should be guided by serum 25(OH)D testing, not arbitrary daily amounts. The Endocrine Society's clinical practice guidelines provide a framework based on current levels:

Deficient (below 20 ng/mL): 4,000-6,000 IU daily for 8-12 weeks, then retest. Some practitioners use higher loading protocols under supervision. The goal is to reach 30 ng/mL before transitioning to maintenance dosing.

Insufficient (20-30 ng/mL): 2,000-3,000 IU daily. Retest at 3 months. Most individuals in this range reach sufficiency within 8-12 weeks at these doses.

Maintenance (30+ ng/mL): 1,000-2,000 IU daily to sustain levels, particularly during winter months or for individuals with limited sun exposure. Maintenance dosing is a long-term commitment, not a temporary intervention.

The tolerable upper intake level (UL) set by the Institute of Medicine is 4,000 IU/day for adults. However, the Endocrine Society and recent research suggest that up to 10,000 IU/day is safe for adults without risk factors for hypercalcemia, particularly during repletion phases. Doses above 4,000 IU/day should be supervised by a healthcare provider with periodic serum monitoring.

Individual factors — body weight, skin pigmentation, geographic latitude, and fat absorption capacity — all influence the dose required to achieve target levels. Testing at 3-month intervals during repletion allows dose adjustment based on actual response rather than population averages.

The conventional advice to "get your vitamin D from the sun" faces several biological and practical limitations that make supplementation necessary for the majority of adults.

SPF 30 sunscreen — the minimum dermatologist-recommended protection — blocks approximately 97% of UVB radiation, which is the specific wavelength required for cutaneous vitamin D3 synthesis. Consistent sunscreen use, while essential for skin cancer prevention, effectively eliminates the skin as a meaningful vitamin D source.

Geographic latitude compounds the problem. Above 37°N latitude (approximately the line from San Francisco to Richmond, Virginia), UVB intensity is insufficient for vitamin D synthesis during winter months — regardless of sun exposure duration. For roughly half the year, residents of northern states, Canada, and Northern Europe cannot produce meaningful vitamin D from sunlight.

Skin pigmentation further modulates synthesis. Melanin acts as a natural UVB filter — individuals with darker skin tones require 3-6x longer UV exposure to produce equivalent D3 compared to lighter-skinned individuals. Combined with indoor-dominant lifestyles and protective clothing, this creates a significant disparity in vitamin D status across populations.

Age-related decline in cutaneous synthesis adds another layer. A 70-year-old produces approximately 25% of the vitamin D3 that a 20-year-old produces from the same sun exposure, due to reduced 7-dehydrocholesterol concentrations in aging skin.

The practical reality: most adults living modern indoor lifestyles above 37°N latitude are functionally supplement-dependent for maintaining optimal vitamin D status, regardless of season. Testing and targeted supplementation — not sun exposure optimization — is the evidence-based approach.